Mankind Pharma has reported results for fourth quarter (Q4) and year ended March 31, 2024.
The company has reported 61.63% rise in its net profit at Rs 454.17 crore for the quarter under review as compared to Rs 280.99 crore for the same quarter in the previous year. Total income of the company increased by 16.82% at Rs 2,236.54 crore for Q4FY24 as compared Rs 1,914.58 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 62.27% rise in its net profit at Rs 476.59 crore for fourth quarter ended March 31, 2024 as compared to Rs 293.70 crore for the same quarter in the previous year. Total income of the company increased by 20.62% at Rs 2,533.23 crore for Q4FY24 as compared Rs 2100.18 crore for the corresponding quarter previous year.
For the year ended March 31, 2024, the company has reported 46.08% rise in its net profit at Rs 1,823.41 crore as compared to Rs 1,248.26 crore for the previous year. Total income of the company increased by 14.98% at Rs 9,531.45 crore for year under review as compared to Rs 8,289.94 crore for year ended March 31, 2023.
For the year ended March 31, 2024, on the consolidated basis, the company has reported 48.26% rise in its net profit at Rs 1,941.77 crore as compared to Rs 1,309.68 crore for the previous year. Total income of the company increased by 19.57% at Rs 10,615.63 crore for year under review as compared to Rs 8,878.00 crore for year ended March 31, 2023.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1808.50 |
Dr. Reddys Lab | 1342.45 |
Cipla | 1472.45 |
Lupin | 2147.55 |
Zydus Lifesciences | 973.90 |
View more.. |